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Chitosan-alginate microparticles of Andrographis paniculata and
Annona muricata extracts for Controlled Release
This study investigates the properties of microparticles prepared 
from Andrographis paniculata (AP) and Annona muricata (AM) 
aqueous extracts for controlled release. Extracts obtained by 
maceration of the dried powdered plant leaves were 
microencapsulated by counterion coacervation method. 
Microcapsules were characterized using Fourier-transform 
infrared-spectroscopy (FTIR), x-ray difractometry (XRD) and 
differential scanning calorimetry (DSC).In vitro release studies 
were carried out at pH 1.2 for 2 h and 6.8 for a further 10 h. 
Release was monitored at274 and 230 nm for AM and AP, 
respectively. Encapsulation efficacy was less than 52% for AP 
and 70% for AM. In vitro drug release at pH 1.2 showed less than 
40% release from the microcapsules after 2h while over 90% of 
extract was released after 6h at pH 6.8. Conventional capsules 
released the content within 1 h in simulated gastric fluid. FTIR, 
XRD and DSC results indicate the stable character of the extract 
within the microcapsules. Microencapsulation with chitosan-
alginate controlled the release of Andrographis paniculata (AP) 
and Annona muricata (AM) aqueous extracts.
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INTRODUCTION
A
ndrographis paniculata (Acanthaceae) also known 
commonly as "King of Bitters," has been used for 
centuries in Asia to treat disorders of the 
gastrointestinal tract and upper respiratory infections, fever, 
herpes, sore throat, and a variety of other chronic and infectious 
diseases[1]. It is found in the Indian Pharmacopoeia and is a 
prominent component in at least 26 Ayurvedic formulas as well as 
in Traditional Chinese Medicine (TCM) [2]. Research conducted 
in the 1980s and 1990s confirmed that when Andrographis is 
properly administered, it has a range of pharmacological effects, 
some of which are extremely beneficial. Andrographolide is the 
principal alkaloid in the plant and it appears to have a relatively 
short half-life of approximately six hours and is excreted by one of 
several routes (urine, faeces, exhaled air, sweat, or other body 
excretions). In some studies, 80 % of the administered dose of 
andrographolide is removed from the body within 8 - 10 h [3,4].
Annona muricata Linn, (Annonaceae) is a popular plant of the 
tropical states of India, America and Africa. The leaves are 
described as evergreen. Phytochemically, it is rich in 
miscellaneous lactones and isoquinoline alkaloids. The leaf, stem, 
bark and seeds contain varying amounts of a novel group of 
chemicals believed to be biologically active, called Annonaceous 
acetogenins [5].The plant extracts have been used traditionally 
for their antimicrobial [6], antidiabetic [7] and antineoplastic [8] 
properties. Its antioxidant activity which was studied as a function 
of its radical DPPH scavenging activity has been reported [9]. It is 
reported to be selectively potent against cancer cells while leaving 
the human cells unharmed [5,8]. Annona muricata leaves are 
mostly used (in capsule form) in the management of cancer due to 
its content of acetogenins. These capsules generally contain the 
powdered leaves administered as 6 to 8 g daily in 3 to 4 divided 
doses. However, the issue of high multiple daily dosing to achieve 
therapy makes them inconvenient for patients. Furthermore, 
treatment for cancer is usually over a long period of time hence 
most patients are usually faced with the challenge of adherence. 
Compounds with short half-life need to be administered often 
since they do not stay in the body for long.
Microencapsulation which involves the reversible coating of 
solids, liquids etc with thin polymeric films will have tremendous 
benefits in taste masking, stability and controlled release. This 
research effort was aimed at formulating Chitosan-alginate 
microcapsules for controlled release of the aqueous extract of 
Andrographis paniculata  and Annona muricata.
Asian J. Pharm. Hea. Sci. | Jan - Mar 2016 | Vol-6 | Issue-1
1378
MATERIALS AND METHODS
Materials
Collection and Identification of Plant material
Extraction
Preparation of microcapsules
Preparation of 0.1 % chitosan solution
Preparation of sodium alginate and aqueous plant extract 
solutions
Microencapsulation process
Fresh leaves of Andrographis paniculata (AP) and Annona 
muricata (AM) were collected in Southern Nigeria and air-dried. 
Chitosan was obtained from Sigma-Aldrich, Germany and 
®
Sodium alginate (Saltiagin ) was a product from Sanofi Bio 
Industries, France. All other chemicals used were of reagent 
grade.
AP and AM leaves were harvested in farms in Benin City, 
Nigeria. Botanical identification was done by Dr Abere Tavs of 
the Department of Pharmacognosy, University of Benin and 
authentication was done by the Forestry Research Institute of 
Nigeria (FRIN), Ibadan, Nigeria. Voucher numbers 107852 (AM) 
and 108458 (AP) were assigned and samples deposited in the 
herbarium of the same Institute. The leaves were plucked off from 
the stem, rinsed and air-dried in a dust-free environment for two 
weeks following which they were pulverized and passed through 
a sieve (1 mm aperture size). The powders collected were 
separately packed in air tight containers prior to utilization.
The powdered sample (100 g) was macerated with 1000 ml of 
distilled water at room temperature for 24 h. The solution was 
vigorously shaken at 30 min interval for the first two hours. The 
extracting solution was filtered and the filtrate obtained was 
o
concentrated to dryness using a vacuum oven at 35 C and the 
dried mass was stored in a refrigerator before drug production. 
Preliminary investigations of the extracts have been reported in a 
previous study [9].
The solution was prepared by dissolving 1 g of chitosan in 500 
ml of distilled water, containing 10 ml of glacial acetic acid, with 
the aid of a magnetic stirrer. Calcium chloride dihydrate (20 g) 
and polysorbate 80 (0.2 ml) were added. The pH of the solution 
was then adjusted to 5.5 using sodium hydroxide solution. The 
solution was filtered and the volume made up to 1000 ml [10].
The dried extract of each plant (2 g) was re-dispersed in 80 ml 
of distilled water with the aid of a magnetic stirrer followed by the 
addition of sodium alginate (2 g), and then stirred until they 
completely dissolved. The volume was then made up to 100 ml 
with more distilled water to give a 2% solution of sodium 
alginate.
The electrostatic droplet generator was used for microcapsule 
preparation. Spherical droplets were formed with a syringe pump 
(Cole-Parmer Instrument Company, USA) to which was fitted a 
o
21G, 90  blunt tip needle (Chromatographic Specialties, Canada) 
through which the mixtures were extruded. The potential 
difference was controlled with a voltage power supply (Model 
30R, Bertan Associates, USA) with a maximum current of 0.4 mA 
and variable voltage of 0 to 30 kV. This had two cables of which 
the 'live' was connected to the needle while the 'ground' cable was 
placed in the collecting solution. The gelation process occurs 
spontaneously due to the formation of calcium-alginate gel 
thereby trapping the extract in the gel matrix. The particles were 
allowed to remain for 2 min after extrusion of alginate/extract 
solution to allow the formation of chitosan coat. The 
microcapsules were then filtered, rinsed with water and air dried 
in an air conditioned room (reduced temperature and humidity) 
for 48 h.
Conventional capsules were also prepared by loading 600 mg 
of dried pulverized leaves (< 0.710 mm) into suitable capsule 
shells.
A light microscope (model 745917, Olympus, Tokyo) with a 
calibrated eyepiece was used to study the size of the particles. All 
particles appearing within each field of view was counted and 
sized with the aid of the calibrated eyepiece graticle. For each 
sample, the diameter of each particle in four representative fields 
of view was used in the size analysis and the mean result 
calculated. 
Microcapsules equivalent to 50 mg of the extract was 
“citrated” by dispersing it in 20 ml of 0.5 M sodium citrate and 
kept overnight (citration was used to breakdown the gel structure 
containing the entrapped dug). The microcapsules, together with 
the citrate solution were then transferred to a glass mortar and 
crushed with a pestle to effect maximum extract release into 
solution [10]. The absorbance of each solution was monitored at 
the respective absorbance of each extract and the EE was 
calculated using Equation 1
EE (%) = Aa/At x 100/1 …………………… (1)
where “Aa” is the absorbance of the actual amount of drug 
present and “At” is the expected absorbance of theoretical drug 
load
Spectra of the microcapsules and dried aqueous extract were 
obtained with a Fourier transform infrared (FTIR) 
spectrophotometer (Jas Co, Italy). The microcapsules and dried 
extracts were crushed to powder with a mortar and pestle. Dried 
potassium bromate powder (200 mg) was blended with 1 to 2 mg 
of the crushed sample. The mixture was then compressed into 
tablet shaped discs. The tablets produced were placed in the 
sample holder of the FTIR spectrometer and their spectra taken 
-1
from 4000 - 1000 nm at a resolution of 4 cm  and 128 scans per 
sample. Plane potassium bromide disc was used as the instrument 
blank.
Thermograms of all the samples were obtained by differential 
scanning calorimetry (DSC 822, Mettler Toledo) equipped with a 
thermokinetic analysis software. Between 5 to 10 mg of the 
microcapsules and dried plant extracts were weighed into sealed 
aluminium pans and the seal was perforated. The pan was placed 
in the DSC combustion chamber while an empty pan was used as 
o
the reference. The equipment was set to heat from 0 to 300 C at a 
o
heating rate of 3 C per min under nitrogen atmosphere with a flow 
o
rate of 75 ml/min. Isothermal condition was maintained at 25 C 
for 5 min. Thermogravimetric analysis (TGA) of all the samples 
were obtained by TA instrument Inc. USA, equipped with 
simultaneous DSC-TGA software. The microcapsules and dried 
plant extracts (10 to 20 mg) were weighed into an aluminium pan. 
The pan was placed in the combustion chamber. The equipment 
Determination of microcapsule size 
Entrapment efficiency (EE)
Fourier-transform infrared (FTIR) spectroscopy
Thermal Analysis
Asian J. Pharm. Hea. Sci. | Jan - Mar 2016 | Vol-6 | Issue-1
1379
o o
was set to heat from 0 to 300 C at a ramp (heating rate) of 10 C per 
min under compressed air with a flow rate of 75 ml/min. 
The X-ray diffraction patterns of the dried plant powders and 
microcapsules were obtained using a Phillips X-ray 
diffractometer equipped with an X'pert Data collector version 3.0 
(Sybase Inc, USA). The microcapsules and dried extracts were 
crushed to powder with a mortar and pestle. The powder was 
spread over a flat disc and levelled to form a plane surface. The 
disc with the powder was placed in the sample holder and the scan 
performed over a wide angle (2θ). The patterns were recorded 
using Cu-Kα radiation at 35 kV and 30 mA for 30 min, continuous 
scan, scanning rate of 0.1deg (Δ2θ)/ 5s (Δt).
In vitro release studies were carried out at pH 1.2 for 2 h and 
6.8 for a further period of 10 h using the USP type 1 (rotating 
basket method) [11]. For each batch, 250 mg microcapsules were 
placed in each dissolution basket and dipped in 500 ml of the 
o
dissolution medium (0.1 M HCl) maintained at 37± 0.5 C and 
then rotated at 100 revolutions per min (rpm) for 2 h. Following 
this 2 h period the basket holder was lifted and immediately 
transferred into another medium containing 500 ml phosphate 
o
buffer (pH 6.8) at 37± 0.5 C and the test continued for another 10 
h. Samples (5 ml) were collected every hour and filtered using a 
Whatmann No. 1 filter paper. After each withdrawal, 5 ml of fresh 
buffer maintained at the same temperature was used to replenish 
the dissolution medium in order to maintain sink conditions. 
Release of the extracts from the microcapsules was monitored 
spectrophotometrically at 274 and 230 nm for AM and AP, 
respectively [12,13]. 
X-ray diffraction Studies
Dissolution studies 
Drug release kinetic
Data analysis
RESULTS
Physical characteristics of the microcapsules
The data obtained from release studies were fitted to various 
release models, namely, zero order, first order, Higuchi, and 
Millar and Peppas using SigmaPlot 8.02 software (Sigma Systat 
Software Inc. CA, USA). These models were first built into the 
regression library of the software (Equations 2  5). The model that 
best represent extract release was determined.
F = Kt …. (2)
-Kt
F =100(1-e ) …. (3)
½
F = Kt      .… (4)
n
F = kt …. (5)
where F = amount of drug released at time t and k = release 
constant and n is the characteristic exponent of the diffusion 
behaviour of swelling controlled release systems [14].
All experiments were conducted in triplicate and the results 
expressed as mean ± standard deviation (SD, n = 3). Statistical 
analysis was carried out using Microsoft Excel, version 2007. 
Differences between means were determined with one-way 
analysis of variance (ANOVA) at level of significance of p< 0.05. 
®
Origin lab  software version 7.0, was used for elaboration of 
spectra data from FTIR, DSC, TGA and XRD.
The wet microcapsules formed were spherical in shape and 
appeared uniform in size distribution. Microcapsules containing 
Figure 1 a and b: DSC thermograms of microcapsules containing Andrographis paniculata andAnnona muricata
Key: AP:  Andrographis paniculata; BM: Blank microcapsules; PA APA: Physical admixtures of AP and alginate; APA: 
microcapsules containing only alginate and AP; AM: Annona muricata; PA AMA: Physical admixtures of AM and alginate 
powder; AMA: microcapsules containing alginate and AM in the core
a. b.
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the leaf extract were green in colour. The microcapsules shrank to 
approximately 10 % of its original wet size and became hard and 
irregular in shape after drying. The mean particle size (µm) ± SD 
produced at 0 kV were 855.5 ± 12.9 and 887.5 ± 12.9 for AP and 
AM, respectively. This size reduced significantly when the 
applied voltage was increased to 10 kV to 273.9 ± 23.6 and 325.9 
± 23.6, respectively. This finding is similar to earlier reports that 
increasing voltage above 6 kV results in decreased microcapsule 
size [15].
There was over 70 % entrapment for microencapsulated 
Annona muricata while microcapsules containing Andrographis 
paniculata extract had over 52 % entrapment. The reason for this 
high entrapment values could be attributed to the spontaneous 
gelation during the encapsulation process. The drying process 
was slow (2 days) though the gelation process was spontaneous. 
The microcapsules were air-dried [16]. This resulted in the 
drainage of some of the extract out of the microcapsules during 
drying. This was more prominent for the Andrographis 
paniculata microcapsules which showed the lowest entrapment. 
The DSC thermograms of the microcapsules shown in
Thermograms
Figure 2 : Representative TGA thermograph of
(A) extracts and (B) microcapsules
Figure 3: X-ray powder diffraction profiles of A: Alginate (a) and 
Blank microcapsules (b); B: Andrographis paniculata (c), 
corresponding physical admixtures with alginate (b) and 
microcapsules (a); C: Annona muricata (c), corresponding 
physical admixtures with alginate (b) and microcapsules (a). 
Key: BM: Blank microcapsules; AP:  Andrographis paniculata; 
PA ApA: Physical admixtures of AP and alginate; APA: 
microcapsules containing only alginate and AP. AM: Annona 
muricata; PA AMA: Physical admixtures of AM and alginate 
powder; AMA: microcapsules containing only alginate and AM 
in the core.
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Figure 4 (a and b): FTIR spectra of (a) AP extract and microcapsules and (b) AM extract and microcapsules
Figure 5: Release of Andrographis paniculata and Anona muricata extract from microcapsules
Key: AP conventional capsules (♦); AM conventional capsules (□); AP microcapsules (Δ); AM microcapsules (x)
Table 1. : Regression coefficient (R2) values for the different release models
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Figures 1a and b, revealed the presence of endothermic peaks in 
o
the range 60 - 120 C, typical of sodium alginate, followed by an 
o
endothermic transition at 175 C in the blank and extract-loaded 
microcapsules. For pure sodium alginate powder, a transition 
o
occurred at 50 - 70 C while the other thermograms obtained from 
o
the microcapsules exhibited broad endotherms over 50 to 150 C 
range. Figure 2 (a and b) are representative TGA thermograms of 
extracts and microcapsules. There was a progressive weight loss 
in all the samples with increase in temperature. The initial loss 
might have been due to moisture loss. This weight loss partly 
confirms that the changes observed in the DSC thermograms 
particularly for the microcapsules were primarily as a result of 
thermal degradation or decomposition. 
The X-ray diffractograms of the microcapsules are shown in 
Figures 3A-C. They indicate that the amorphous sodium alginate 
(curve 'a' of Figure 3A) and chitosan reacted with the crystalline 
calcium chloride to form a complex (chitosan-alginate) with 
o
crystalline peak at 32 (curve 'b' of Figure 3A).
The FTIR spectra of microcapsules are shown in Figures 4a 
and b, the spectra revealed obvious similarities in the functional 
groups of the primary constituents of the extracts and 
microcapsules, with characteristic absorption spectra for OH 
-1
stretching at wave number of 3400-3550 cm , and CH stretching 
-1
of CH  and CH  at wave number of 1922 cm . There was no 
2 3
change in the functional groups of the different compounds in the 
microcapsules before and after extract encapsulation. This 
indicates that there was no chemical reaction between the extracts 
and other materials in the formulation.
The effect of microencapsulation on the release of the extract 
from microcapsules is shown in Figure 5. In simulated gastric 
fluid (pH 1.2), the conventional capsule formulations released 
completely the extract within 1 h while the microcapsule 
formulations demonstrated reduced extract release by up to 50% 
in the first 2 h.
A number of formulations containing Andrographis 
paniculata have been reported [16]. It is also an ingredient in 
some herbal formulations and bitters. These commercial 
formulations are however very bitter and the andrographolides 
have a relatively short half-life (6.6 h) after oral administration [4] 
hence warranting frequent administration. This renders it difficult 
to formulate stable preparations with prolonged release. The DSC 
thermograms of APand AM extracts showed a pronounced 
o
endothermic peak as the temperature was increased from 25 C. 
Andrographis paniculata dried extract showed a transition 
o
endotherm at 100 to 110 C followed by decomposition between 
o
90 and 125 C. Plant extracts comprise a wide variety of materials 
from components like calcium oxalate to macromolecules like 
sugars, proteins and a vast array of secondary metabolites [17]. 
The presence of all these components in the extracts was 
responsible for the broad endothermic peak observed in the DSC 
study since they undergo decomposition at different times and 
under different thermal conditions. These endotherms are 
attributed to the presence of large varieties of secondary 
metabolites and sugars in the extracts including the fact that 
sodium alginate is a complex macromolecule polymer [18]. The 
X-ray diffractograms
FTIR spectra
Drug release 
DISCUSSION 
endotherm for sodium alginate powder disappeared when used in 
microencapsulation, due to the formation of a new compound 
(calcium-alginate). The blank microcapsules (BM) had a similar 
thermogram as those containing the extracts, thus suggesting that 
the reaction of sodium alginate and calcium chloride resulted in 
the formation of the new thermograms observed. The 
thermograms of the new complex formed appeared not to have 
been affected by the inclusion of the extract while the physical 
admixtures of sodium alginate and dried plant extract did not 
affect the endotherm of the pure sodium alginate.
The XRD of blank microcapsules (BM) indicate their 
° 
crystalline nature with a peak at 32 (curve b of Figure 3A). The 
crystalline peaks of calcium-alginate did not shift when the 
extracts were incorporated in the microcapsules (curve a, of 
Figure 3B,C). Thus the crystalline properties of the chitosan-
alginate microcapsules were not affected by the presence of the 
extracts. Annona muricata extract on the other hand showed a 
°
crystalline peak at 28  (curve c, of Figure 3C). BM and AM peaks 
were distinct and there was no shift and no creation of new peak 
was observed following the incorporation of Annona muricata 
extract into the microcapsules (curve c, of Figure 3C). These data 
strongly suggest that the crystal structure of extracts was not 
affected by encapsulation process.
The AM microcapsules released up to 60 % of the extract 
while those of AP released 40 % of the extract. A. muricata extract 
was more soluble in the release medium and therefore diffused 
out of the microcapsules more rapidly. Nevertheless, extract 
release from the microcapsules was considerably slower than 
from the conventional capsule preparation of finely powdered 
leaves of AM or AP). The initial high amount released may be due 
to the fact that the extract diffused from the microcapsule core to 
its surface during drying. This in itself may be beneficial where 
continuous drug release is desired, as the remaining 55 - 65 % of 
the extract in the microcapsules was released over the next 5 h 
when the microcapsules were transferred to simulated intestinal 
fluid (SIF).When the microcapsules were transferred into 
phosphate buffer (pH 6.8) (simulated intestinal fluid) and 
dissolution continued for another 10 h, maximum release was 
achieved from AMA microcapsules after 8 h. Annona muricata 
leaves are mostly used (in capsule form) in the management of 
cancer due to its content of annonaceous acetogenins. These 
capsules generally contain the powdered leaves administered as 4 
to 6 g daily in 3 to 4 divided doses. However, the issue of high 
multiple daily dosing to achieve therapy makes them 
inconvenient for patients hence the potential benefit of these 
microcapsules. 
2
Table 1 presents the regression coefficient (R ) values for the 
 2
release models to which the extract release data were fitted.The R  
values were above 0.9 for first order, and Millar and Peppas. 
While a reasonable amount of the extract diffused out at acid pH, 
often the bulk of the extract diffused out at pH 6.8. The 
microcapsules fitted more closely to first order model followed by 
Millar and Peppas model. Thus, extract diffusion decreased in 
proportion to the amount of extract remaining in the 
microcapsule. All the formulations fitted poorly to zero order and 
Higuchi models. Extract release from microcapsules was by 
matrix-diffusion mechanism
Formulations of the aqueous extracts of these plants in 
chitosan-alginate microcapsules slowed down in vitro release of 
the extracts. This work indicates that it is feasible to formulate 
CONCLUSION
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herbal extracts into microcapsules with the aim of reducing 
dosing frequency. The successful application of this technology to 
two different plants with very different constituents suggests that 
the technique can also be applied to a wide variety of plant 
extracts from different sources.
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